Prostate Cancer Genomic Test Predicted Progression Risk
A genomic risk score helped identify California men on active surveillance more likely to see disease advancement.
Updated on Sept. 22, 2026 in Men’s Health
Live Poll
Do you believe genomic testing helps patients better manage long-term health surveillance and treatment decisions?
Research published January 31, 2026, found that a high Decipher genomic risk score was associated with a higher likelihood of prostate cancer progression. The study analyzed 486 men to determine if this RNA-based test could help better manage those on active surveillance.
Why it matters
Active surveillance monitors low-risk prostate cancer to avoid immediate, potentially unnecessary treatment. This genomic tool may eventually allow clinicians to tailor surveillance intensity based on a patient's biological risk of disease progression.
In a cohort of 486 men with a median age of 64, researchers found that high-risk Decipher scores (at least 0.6) correlated with significantly higher rates of biopsy upgrading and unfavorable histology over a median follow-up of 78 months.
The players
University of California, San Francisco
A public research university and medical center whose database provided the patient records for this analysis.
The details
The Decipher genomic classifier functions as a whole-transcriptome RNA assay that provides a score between 0 and 1 to estimate metastatic potential. By identifying specific gene expression patterns, the test aims to provide a biological assessment of tumor behavior that goes beyond traditional clinicodemographic factors. This provides additional data for physicians evaluating whether a patient's disease is truly indolent or likely to require more intensive monitoring.
Timeline
The study results were published online on January 31, 2026.
A follow-up report on these findings was published on September 22, 2026.
Health Landscape
This research reflects the broader movement toward precision medicine in prostate cancer care, where genomic classifiers are being tested to supplement standard clinical markers. It follows a trend of shifting from purely clinical monitoring to biologically informed risk stratification for men on active surveillance.
If you are currently on active surveillance for prostate cancer, this research is worth discussing with your urologist to understand if your care team uses genomic testing. Ask your doctor whether your current monitoring plan is based solely on clinical markers or if genomic risk assessments are appropriate for your individual case.
The takeaway
Genomic testing for prostate cancer is evolving as a way to potentially identify which patients on active surveillance require closer observation. Consider asking your physician about the current role of biomarker and genomic testing in your ongoing cancer care plan.
What happens next
Researchers are planning prospective evaluations to determine if using these risk-adapted protocols in clinical settings is effective.
Further reading
For more on managing prostate conditions, visit Men’s Health.
Source note: This article includes information reported by Renal and Urology News.
Live Poll
Do you believe genomic testing helps patients better manage long-term health surveillance and treatment decisions?
